Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in locally advanced head and neck squamous cell carcinoma (LA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Squamous Cell of Head and Neck
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• JNJ-90301900

Snippet

Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Conditions: Carcinoma, Squamous Cell | Phase 3 | Status: RECRUITING